TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06254534

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: optic nerve ultrasonography
Description: The primary investigator measured ONSD at times: first after anesthesia induction before laryngoscopy, second just after laryngoscopy, third five minutes after, and fourth ten minutes after intubation by ultrasound guidance with a high-frequency linear probe at T2 ophthalmic preset.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: optic nerve ultrasonography
Description: The primary investigator measured ONSD at times: first after anesthesia induction before laryngoscopy, second just after laryngoscopy, third five minutes after, and fourth ten minutes after intubation by ultrasound guidance with a high-frequency linear probe at T2 ophthalmic preset.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: optic nerve ultrasonography
Description: The primary investigator measured ONSD at times: first after anesthesia induction before laryngoscopy, second just after laryngoscopy, third five minutes after, and fourth ten minutes after intubation by ultrasound guidance with a high-frequency linear probe at T2 ophthalmic preset.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: optic nerve ultrasonography
Description: The primary investigator measured ONSD at times: first after anesthesia induction before laryngoscopy, second just after laryngoscopy, third five minutes after, and fourth ten minutes after intubation by ultrasound guidance with a high-frequency linear probe at T2 ophthalmic preset.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: optic nerve ultrasonography
Description: The primary investigator measured ONSD at times: first after anesthesia induction before laryngoscopy, second just after laryngoscopy, third five minutes after, and fourth ten minutes after intubation by ultrasound guidance with a high-frequency linear probe at T2 ophthalmic preset.
Study: NCT04729894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Lockbox
Description: Participants will receive a medication lockbox to store medications in their home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants will receive information on safe medication storage practices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants will receive information on safe medication storage practices.
Study: NCT06037590

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Levodopa Cyclops™
Description: Orally inhaled dry powder levodopa from the Cyclops™ dry powder inhaler

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Levodopa Cyclops™
Description: Orally inhaled dry powder levodopa from the Cyclops™ dry powder inhaler

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Levodopa Cyclops™
Description: Orally inhaled dry powder levodopa from the Cyclops™ dry powder inhaler

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: INBRIJA®
Description: Orally inhaled dry powder levodopa from the ARCUS® dry powder inhaler
Study: NCT02987257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Harmonized supportive care
Description: Harmonized supportive care with and etanercept placebo days 1 and 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Harmonized supportive care
Description: Harmonized supportive care with and etanercept placebo days 1 and 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept 50 mg sc day 1 and day 4
Description: Harmonized supportive care with placebo
Study: NCT06203886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LumbaCure
Description: LumbaCure® is a device developed to induce specific mobilization of the lower back in patients requiring physical rehabilitation for orthopaedic disorders, particularly chronic low back pain.
Study: NCT05390268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile app-assisted behavioral treatment
Description: The app-assisted training group has access to a newly developed app in which they are taught how to handle tics. A new app session is released at each new treatment session and the content of the app videos is comparable to the information and training at face-to-face individual treatment, as defined by the manual Niks to Tics\[

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobile app-assisted psychoeducation
Description: The app-assisted educational group has access to a newly developed app in which they receive psychoeducation on tics.
Study: NCT06307613

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Efgartigimod PH20 SC
Description: Subcutaneous efgartigimod PH20 SC given by prefilled syringe

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PH20 SC
Description: Subcutaneous placebo given by prefilled syringe
Study: NCT06651086

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unstuck and On Target
Description: Unstuck and on Target (Unstuck; Cannon et al., 2021) is a cognitive-behavioral, intervention designed to be feasibly delivered by teachers and school staff in the elementary school setting. It was adapted for and pilot-tested in outpatient mental health. Unstuck targets key executive functions, including flexibility, goal-setting, planning, and coping. Sessions include prescribed content and activities to facilitate guided practice and home extension activities to aid generalization beyond the therapeutic session. It includes both child- and caregiver-directed strategies. It has been shown effective for youth with autism and attention-deficit/hyperactivity disorder.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unified Protocol for Children
Description: Unified Protocol for Children is a transdiagnostic, cognitive-behaviorally based treatment targeting shared core dysfunctions underlying emotional disorders, including distress intolerance and emotional dysregulation. It was developed by integrating cognitive-behavioral and mindfulness strategies and includes prescribed activities, in-vivo experiments, and home-extension components to promote generalization. It includes both child- and caregiver-directed strategies. In addition to its effectiveness for youth with emotional disorders, recent work supports its efficacy for youth with additional non-emotional disorders (e.g., externalizing challenges, irritability).
Study: NCT06406088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EarGenie MVP test
Description: The EarGenie MVP test consists of placing the EarGenie headgear containing light emitting diodes (LEDs) and light detectors on the infant and running the fNIRS tests of sound detection or sound discrimination via the user interface. Blocks of speech sounds are presented to the infant via earphones or via speaker, and the EarGenie MVP measures changes in the blood oxygenation in temporal and prefrontal regions of the cortex. Automatic analyses are run to determine whether the infant heard the sounds (at levels 35, 50, and 65 dBSPL) or discriminated between two sounds (Ba/Tea, Ba/Bee, or Ba/Ga). The infant will be in a natural sleep or quiet awake state when the fNIRS test is run. Prior to the test, standard audiometric procedures (otoscopy and tympanometry) will confirm normal middle ear function.
Study: NCT05667467

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Care Bundle Implementation
Description: In this study, the control group received standard care. The nurse group was given training on the implementation of the care bundle. A cardiac surgery care bundle was applied to the study group by clinical nurses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Care Bundle Implementation
Description: In this study, the control group received standard care. The nurse group was given training on the implementation of the care bundle. A cardiac surgery care bundle was applied to the study group by clinical nurses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Care Bundle Implementation
Description: In this study, the control group received standard care. The nurse group was given training on the implementation of the care bundle. A cardiac surgery care bundle was applied to the study group by clinical nurses.
Study: NCT06320301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab + GEMOX + TKI
Description: Adebrelimab 20 mg/kg, once every 3 weeks (Q3W), maintained for 1 year. The interval between two doses should not be less than 12 days.~Tyrosine kinase inhibitor (TKI) Lenvatinib: 12 mg (3 capsules 4 mg) or 8 mg (2 capsules 4 mg) once daily (QD) at fixed times daily, on an empty stomach or with food; Apatinib: 250mg orally, QD, 5 days of medication, 2 days off (5 on 2 off) or once every other day (QOD), half an hour after meals; Sorafenib: 0.4g (2 × 0.2g) twice or once daily on an empty stomach or with a low-fat or medium-fat diet Anlotinib: 12 mg orally before breakfast, QD. The drug was taken continuously for 2 weeks and stopped for 1 week.~GEMOX: gemcitabine 800mg/m2 and oxaliplatin 85mg/m2, intravenous infusion, D2, D15, D29, until 6 cycles of treatment were completed, or the patients who did not reach 6 cycles had intolerable adverse reactions, then the combination chemotherapy was terminated.
Study: NCT05530590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training to Serve (TTS) in person training
Description: Participants receive in person training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training to Serve online training (eTTS)
Description: Participants receive online training.
Study: NCT04882774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Diolamine
Description: Oral treprostinil 0.125 mg TID titrated as clinically indicated and tolerated to a maximum of 6 mg TID
Study: NCT05145725

Intervention type: BEHAVIORAL
Intervention: Quality of life questionnaires
Description: Different questionnaires to fill : SRS-22r, SF-36 score, TAPS, KIDSCREEN10
Study: NCT05396989

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06185010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One Resistance Training Set (Single Session)
Description: The participants will perform a resistance training session with one set per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 1 set of 10 repetitions at 60% of one-repetition maximum (1RM) in the leg press, iii) 1 set of 10 repetitions at 55% 1RM in the chest press, iv) 1 set of 10 repetitions in the sit-to-stand exercise, v) 1 set of 10 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three Resistance Training Sets (Single Session)
Description: The participants will perform a resistance training session with three sets per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 3 sets of 10 repetitions at 60% of one-repetition maximum (1RM) in the leg press, iii) 3 sets of 10 repetitions at 55% 1RM in the chest press, iv) 3 sets of 10 repetitions in the sit-to-stand exercise, v) 3 sets of 10 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One Resistance Training Set (8 Weeks)
Description: The participants will perform eight weeks of resistance training with one set per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 1 set of 10 repetitions between 50-70% of one-repetition maximum (1RM) in the leg press, iii) 1 set of 10 repetitions between 40-60% 1RM in the chest press, iv) 1 set of 6-12 repetitions in the sit-to-stand exercise, v) 1 set of 6-12 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three Resistance Training Sets (8 Weeks)
Description: The participants will perform eight weeks of resistance training with three sets per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 3 sets of 10 repetitions between 50-70% of one-repetition maximum (1RM) in the leg press, iii) 3 sets of 10 repetitions between 40-60% 1RM in the chest press, iv) 3 sets of 6-12 repetitions in the sit-to-stand exercise, v) 3 sets of 6-12 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (8 Weeks)
Description: The participants in the control group will maintain their regular daily activities without performing any form of physical exercise.
Study: NCT06445790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy for Chronic Pelvic Pain-CBT-cp
Description: CBT-cp will be administered weekly sessions for 12 weeks.
Study: NCT04880707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Twin block local anesthetic nerve block using standard dental anesthetic
Description: 2% lidocaine with 1:100,000 epinephrine is the standard dental local anesthetic in universal use. This drug will be administered as the Twin block local anesthetic nerve block targeting the branches of the mandibular nerve supplying the temporalis and masseter muscles.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Twin block with placebo
Description: Instead of the standard dental anesthetic, sterile normal saline will be delivered using the Twin block injection
Study: NCT06462820

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active SAINT Stimulation
Description: Participants who are randomly assigned to this group will receive active SAINT targeted to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system with the Cool-B65 A/P coil.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham SAINT Stimulation
Description: Participants who are randomly assigned to this group will receive sham stimulation targeted to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system with the Cool-B65 A/P coil.
Study: NCT05193071

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin 100mg; Clopidogrel 300mg
Description: Aspirin 100mg plus Clopidogrel 300mg will be orally administrated after randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg; Clopidogrel 300mg
Description: Aspirin 100mg plus Clopidogrel 300mg will be orally administrated after randomization
Study: NCT04197648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: 24 week supervised exercise program (strength and cardiovascular program).
Study: NCT05794802

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BHB supplement
Description: Oral consumption of 0.5 g/kg of a BHB supplement (KE4; Ketoneaid®, Falls Church, Virginia, USA)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: 80 to 120 ml of a placebo solution, depending on the participant's body weight, with the addition of stevia and bitter agent solution (Bitrex, Scotland, UK) as well as the same flavouring as the ketone supplement drink (provided by Ketoneaid)
Study: NCT06389201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ
Description: HCQ, 400-600mg, oral tablet, once, one day before chemotherapy and radiotherapy. During therapy, HCQ maintenance dose is 200-400mg daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral tablet, once, one day before chemotherapy and radiotherapy. During therapy, placebo maintenance oral tablet once daily.
Study: NCT06260423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experienced dentist using lateral compaction with bioceramic sealer.
Description: Root canal treatment using bioceramic sealers.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unexperienced dentist using lateral compaction with bioceramic sealer.
Description: Root canal treatment using bioceramic sealers.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experienced dentist using Single cone with bioceramic sealer.
Description: Root canal treatment using bioceramic sealers.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unexperienced dentist using Single cone with bioceramic sealer.
Description: Root canal treatment using bioceramic sealers.
Study: NCT06444256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUVO
Description: Participants will receive 20mg of SUVO for 7 days in the evening before bed on Day 5 through Day 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAU
Description: Participants will receive supportive care and symptomatic medication per protocol at the inpatient facility.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Participants will receive supportive care and symptomatic medication per protocol at the inpatient facility.
Study: NCT06371495

Intervention type: DRUG
Intervention: rosuvastatin
Description: Stude include three groupsof people GroupA: recieve rosuvastatin 40mg Group B :recive rosuvastatin 20mg Group C: recive placebo 2- Follow up will be done using NIHSS at the onset and modified Rankin scale at the onset and after 1 month and 3 months of the onset.~3- Carotid duplex will be done at the onset and after 1 month and 3 months of the onset.

Intervention type: DRUG
Intervention: rosuvastatin
Description: Stude include three groupsof people GroupA: recieve rosuvastatin 40mg Group B :recive rosuvastatin 20mg Group C: recive placebo 2- Follow up will be done using NIHSS at the onset and modified Rankin scale at the onset and after 1 month and 3 months of the onset.~3- Carotid duplex will be done at the onset and after 1 month and 3 months of the onset.
Study: NCT06045455

Intervention type: DIAGNOSTIC_TEST
Intervention: Multimodal brain CT
Description: Multimodal brain CT includes NCCT, CTP, and CTA

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging (MRI)
Description: MRI examination will be performed between the 3rd and 7th day after the admission to the hospital
Study: NCT05684575

Intervention type: OTHER
Group type: OTHER
Intervention: Phone satisfaction questionnaire
Description: Evaluation of the outcome of Covid-19 patients discharged home on oxygen therapy
Study: NCT05902273

Intervention type: DIAGNOSTIC_TEST
Intervention: hemodynamic monitoring
Description: Baxter Starling Monitor for measuring cardiac output and systemic vascular resistance (SVRI) which is using bioreactance technology. We need to place four electrodes on chest wall (upper left, upper right, down left, down right) and input monitor demographic parameters. Also enter mean arterial pressure (MAP) for calculating SVRI so we input MAP every minute.Patient bed set as 45 degree head elevated and legs 0 degree. Just after start measuring, monitor needs to synchronize itself for patient. After synchronisation we start fluid challenge with passive leg raising option. This test has two stages. First stage calculating baseline parameters which takes 3 minutes and second stage is measuring difference with fluid challenge which also takes 3 minutes. At the end of first stage monitor shows to perform passive leg raise and we perform trendelenburg maneuver till head comes to 0 degree. After second stage measurement has finished.

Intervention type: DIAGNOSTIC_TEST
Intervention: resistive index
Description: We use ultrasonography at the same time with cardiac output monitor in both stages. First we determine the location of radial artery at wrist snuffbox at 1.5 centimeters depth with linear probe and confirm pulsatile flow with color mode. In Starling's baseline stage we measure and calculate resistive index with doppler P-mode in triplex setting 3 times. When received 3 same result successively we noted as SBRI-1. Second measurement is initiated at last 30 seconds of passive leg raising as described before and we noted our measurement as SBRI-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Pleth variability index
Description: During all stages Masimo Rad-87 rainbow probe is placed patients index or middle finger and we note PVI-1 and PVI-2 at the same time with SBRI-1 and SBRI-2
Study: NCT05021874

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Four different physiotherapy treatment
Description: Four different physiotherapy treatment will be used for, to reduce pain and tension in the masseter muscles. The assessment of pain intensity on the VAS scale will be assessed each time after the therapy. After the 10th day of therapy, it will be measured ROM.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Four different physiotherapy treatment
Description: Four different physiotherapy treatment will be used for, to reduce pain and tension in the masseter muscles. The assessment of pain intensity on the VAS scale will be assessed each time after the therapy. After the 10th day of therapy, it will be measured ROM.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Four different physiotherapy treatment
Description: Four different physiotherapy treatment will be used for, to reduce pain and tension in the masseter muscles. The assessment of pain intensity on the VAS scale will be assessed each time after the therapy. After the 10th day of therapy, it will be measured ROM.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Four different physiotherapy treatment
Description: Four different physiotherapy treatment will be used for, to reduce pain and tension in the masseter muscles. The assessment of pain intensity on the VAS scale will be assessed each time after the therapy. After the 10th day of therapy, it will be measured ROM.
Study: NCT04900350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: Subjects receive AK117 intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subjects receive Azacitidine subcutaneously.